Quick Answer
Vivos Therapeutics, Inc. reported Gross Profit of $9.02 million for fiscal year 2024.
Vivos Therapeutics, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2024 | $9.02M | +9.0% |
| 2023 | $8.27M | -17.4% |
| 2022 | $10.02M | -20.5% |
| 2021 | $12.60M | +21.0% |
| 2020 | $10.41M | +20.3% |
| 2019 | $8.66M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.94M | +68.7% | +86.6% |
| June 30, 2025 | $2.11M | -20.4% | +39.8% |
| March 31, 2025 | $1.51M | -22.1% | -35.3% |
| September 30, 2024 | $2.33M | +33.6% | -12.0% |
| June 30, 2024 | $2.65M | +26.4% | +36.9% |
| March 31, 2024 | $1.94M | -17.1% | +10.9% |
| September 30, 2023 | $1.75M | -30.0% | -16.7% |
| June 30, 2023 | $2.10M | -18.9% | -10.2% |
- Vivos Therapeutics, Inc. showed an increase of +9.0% in Gross Profit compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s gross profit has grown by 4.2% (from $8.66 million to $9.02 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: